University Of Massachusetts Amherst
Treatments that ‘revolutionized cancer therapy’ may increase risk for bone damage
To help individuals who undergo cancer treatment lead healthier lives, Stacyann Bailey, PhD, has one overarching professional mission — to prevent bones from breaking.
Diabetes-related mortality, pediatric DKA rates increased during COVID-19 pandemic
Most studies found increases in diabetes-related mortality for adults and diabetes ketoacidosis incidence among youths during the COVID-19 pandemic compared with before the pandemic, according to a systematic review.
E-cigarette use vs. nicotine replacement therapy leads to higher quit rates
Individuals using nicotine e-cigarettes have a higher likelihood of quitting smoking compared with nicotine replacement therapy users, according to data published in Cochrane Database of Systematic Reviews.
Exposure to endocrine-disrupting chemicals may lower odds for achieving pregnancy
Exposure to endocrine-disrupting phthalates may reduce women’s fecundability, or odds of becoming pregnancy during a menstrual cycle, according to findings published in Environmental Health Perspectives.
Eprenetapopt regimen beneficial after HSCT for TP53-mutant AML, myelodysplastic syndrome
Maintenance therapy with eprenetapopt plus azacitidine after hematopoietic stem cell transplantation led to improved survival outcomes among patients with TP53-mutant acute myeloid leukemia or myelodysplastic syndrome, study results showed.
Vitamin D2 supplement may slow progression of new-onset type 1 diabetes in children
A supplement of Vitamin D2 may improve insulin sensitivity and slow the increase of HbA1c for children and adolescents with new-onset type 1 diabetes, according to study findings published in the Journal of the Endocrine Society.
SURPASS-5: Tirzepatide lowers HbA1c in adults with type 2 diabetes on insulin glargine
Adults with type 2 diabetes assigned tirzepatide alongside insulin glargine had greater reductions in HbA1c and body weight compared with placebo, according to data from the SURPASS trial program.
Ficlatuzumab plus chemotherapy effective in relapsed or refractory acute myeloid leukemia
Ficlatuzumab plus single-agent chemotherapy showed encouraging efficacy and appeared safe among patients with relapsed or refractory acute myeloid leukemia, according to phase 1 study results published in Blood Cancer Discovery.
Aspacytarabine a potential first-line option for chemotherapy-ineligible patients with AML
The novel antimetabolite aspacytarabine appeared safe and efficacious as first-line therapy for patients with acute myeloid leukemia unfit for intensive chemotherapy, according to a study presented during the virtual ASCO Annual Meeting.
Acalabrutinib confers equal PFS with less toxicity vs. ibrutinib in previously treated CLL
Acalabrutinib proved noninferior to ibrutinib in terms of PFS and resulted in less cardiotoxicity and fewer discontinuations due to adverse effects in a head-to-head trial among patients with previously treated chronic lymphocytic leukemia.